An open-label, partially randomized, cross-over, monocentric phase I study evaluating the pharmacokinetic profile of RhuDex [AV-1142742] in order to determine optimum doses of meglumine and RhuDex.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2018
At a glance
- Drugs AV 1142742 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors MediGene Ltd
- 28 Nov 2007 Status changed from recruiting to completed.
- 02 Oct 2007 New trial record.